Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price fell 18.2% during trading on Thursday . The company traded as low as C$0.18 and last traded at C$0.18. 7,500 shares were traded during trading, a decline of 60% from the average session volume of 18,857 shares. The stock had previously closed at C$0.22.
Devonian Health Group Trading Down 18.2 %
The company’s 50 day simple moving average is C$0.22 and its two-hundred day simple moving average is C$0.18. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The company has a market capitalization of C$26.68 million, a price-to-earnings ratio of -9.00 and a beta of 1.28.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- How to Calculate Stock Profit
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- How to Most Effectively Use the MarketBeat Earnings Screener
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- Best Aerospace Stocks Investing
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
